David G Kiely

List of Publications by Year
in descending order

181 papers	9,936 citations	53939 47 h-index	43601 95 g-index
184 all docs	184 docs citations	184 times ranked	8128 citing authors

#	Article	IF	Citations
1	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	3.1	31
2	The REPAIR Study. JACC: Cardiovascular Imaging, 2022, 15, 240-253.	2.3	28
3	Computed tomography lung parenchymal descriptions in routine radiological reporting have diagnostic and prognostic utility in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with lung disease. ERJ Open Research, 2022, 8, 00549-2021.	1.1	7
4	Comment on â€œExternal validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertensionâ€• ERJ Open Research, 2022, 8, 00066-2022.	1.1	0
5	Elective lower limb orthopedic arthroplasty surgery in patients with pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12019.	0.8	2
6	CMR Measures of Left Atrial Volume Index and Right Ventricular Function Have Prognostic Value in Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Medicine, 2022, 9, 840196.	1.2	2
7	Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. Frontiers in Cardiovascular Medicine, 2022, 9, 797561.	1.1	7
8	Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 81-93.	2.5	9
9	Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements. Journal of Cardiovascular Magnetic Resonance, 2022, 24, 25.	1.6	8
10	Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomography. ERJ Open Research, 2022, 8, 00503-2021.	1.1	10
11	Examining the impact of pulmonary hypertension on nonprofessional caregivers: A mixedâ€methods systematic review. Pulmonary Circulation, 2022, 12, e12077.	0.8	3
12	Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response. Heart, 2022, 108, 1392-1400.	1.2	15
13	Machine learning cardiac-MRI features predict mortality in newly diagnosed pulmonary arterial hypertension. European Heart Journal Digital Health, 2022, 3, 265-275.	0.7	11
14	Validation of Artificial Intelligence Cardiac MRI Measurements: Relationship to Heart Catheterization and Mortality Prediction. Radiology, 2022, 305, 68-79.	3.6	12
15	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respiratory Medicine,the, 2022, 10, 937-948.	5.2	57
16	Quantitative CT Evaluation of Small Pulmonary Vessels Has Functional and Prognostic Value in Pulmonary Hypertension. Radiology, 2022, 305, 431-440.	3.6	4
17	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	1.6	29
18	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. European Respiratory Journal, 2021, 57, 2000124.	3.1	29

#	Article	IF	Citations
19	Current and future treatments of pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 6-30.	2.7	104
20	Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging, 2021, 14, 931-942.	2.3	73
21	Right Ventricular Adaptation Assessed Using Cardiac Magnetic Resonance Predicts Survival in Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging, 2021, 14, 1271-1272.	2.3	11
22	Patterns of thromboembolic pulmonary vascular disease in COVIDâ€19. Pulmonary Circulation, 2021, 11, 1-3.	0.8	5
23	Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2021, 18, 34-43.	1.5	13
24	Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. ERJ Open Research, 2021, 7, 00046-2021.	1.1	15
25	Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. Thorax, 2021, 76, 1032-1035.	2.7	13
26	Outcome Measures Used in Studies of Rehabilitation in Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 321-335.	1.5	3
27	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. British Journal of Anaesthesia, 2021, 126, 774-790.	1.5	45
28	Pulmonary Hypertension in Association with Lung Disease: Quantitative CT and Artificial Intelligence to the Rescue? State-of-the-Art Review. Diagnostics, 2021, 11, 679.	1.3	15
29	Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 3019-3025.	0.7	12
30	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. Annals of the American Thoracic Society, 2021, 18, 981-988.	1.5	28
31	Myocardial T1-mapping and extracellular volume in pulmonary arterial hypertension: A systematic review and meta-analysis. Magnetic Resonance Imaging, 2021, 79, 66-75.	1.0	16
32	Establishing expert consensus for the optimal approach to holistic risk-management in pulmonary arterial hypertension: a Delphi process and narrative review. Expert Review of Respiratory Medicine, 2021, 15, 1493-1503.	1.0	0
33	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Research, 2021, 7, 00850-2020.	1.1	65
34	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine, 2021, 69, 103444.	2.7	30
35	Integrated Cardiopulmonary MRI Assessment of Pulmonary Hypertension. Journal of Magnetic Resonance Imaging, 2021, , .	1.9	7
36	Pulmonary hypertension phenotypes in patients with systemic sclerosis. European Respiratory Review, 2021, 30, 210053.	3.0	27

#	Article	IF	Citations
37	Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow. European Respiratory Journal, 2021, 58, 2102008.	3.1	6
38	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and singleâ€arm efficacy. Pulmonary Circulation, 2021, 11, 1-12.	0.8	5
39	A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis. European Heart Journal Cardiovascular Imaging, 2021, 22, 236-245.	0.5	40
40	19â€…Cardiac magnetic resonance to identify raised left ventricular filling pressure. , 2021, , .		2
41	Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	2.5	80
42	Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 458-468.	2.5	99
43	A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Haemostasis, 2020, 18, 114-122.	1.9	81
44	MRI Prediction of Precapillary Pulmonary Hypertension according to the Sixth World Symposium on Pulmonary Hypertension. Radiology, 2020, 294, 482-482.	3.6	10
45	CIPHER AND CIPHER-MRI: TWO PROSPECTIVE, MULTICENTER STUDIES FOR THE IDENTIFICATION OF BIOMARKER SIGNATURES FOR EARLY DETECTION OF PULMONARY HYPERTENSION. Chest, 2020, 158, A2191-A2193.	0.4	0
46	EFFECT OF MACITENTAN ON CARDIAC FUNCTION IN PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE REPAIR ECHOCARDIOGRAPHY SUBSTUDY. Chest, 2020, 158, A2224-A2227.	0.4	0
47	Age-associated changes in 4D flow CMR derived Tricuspid Valvular Flow and Right Ventricular Blood Flow Kinetic Energy. Scientific Reports, 2020, 10, 9908.	1.6	13
48	Cardiac Magnetic Resonance in Pulmonary Hypertensionâ€”an Update. Current Cardiovascular Imaging Reports, 2020, 13, 30.	0.4	16
49	Mild parenchymal lung disease is still lung disease. European Respiratory Journal, 2020, 56, 2003727.	3.1	3
50	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation, 2020, 142, 1464-1484.	1.6	96
51	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594.	2.5	45
52	Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 2000041.	3.1	48
53	BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?. European Respiratory Review, 2020, 29, 200009.	3.0	51
54	Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. European Radiology, 2020, 30, 4918-4929.	2.3	29

#	Article	IF	Citations
55	Partial anomalous pulmonary venous drainage in patients presenting with suspected pulmonary hypertension: A series of 90 patients from the ASPIRE registry. Respirology, 2020, 25, 1066-1072.	1.3	10
56	Editorial: Pulmonary Hypertension: Mechanisms and Management, History and Future. Frontiers in Medicine, 2020, 7, 125.	1.2	1
57	Pulmonary Hypertension and Pregnancy. , 2020, , 99-112.		1
58	Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). JACC: Cardiovascular Interventions, 2020, 13, 989-999.	1.1	47
59	Idiopathic pulmonary arterial hypertension and coâ€existing lung disease: is this a new phenotype?. Pulmonary Circulation, 2020, 10, 1-8.	0.8	16
60	Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?. European Respiratory Journal, 2020, 56, 1902334.	3.1	1
61	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. Frontiers in Cardiovascular Medicine, 2020, 7, 51.	1.1	16
62	Cardiac MRI for Prognosis in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. , 2020, , .		1
63	Serial cardiac MRI for assessment of cardiac morphology and function in CTEPH patients after PEA or vasodilator therapy. , 2020, , .		0
64	Adultsâ€™ experiences of living with pulmonary hypertension: a thematic synthesis of qualitative studies. BMJ Open, 2020, 10, e041428.	0.8	10
65	Sex bias exists in diagnosing pulmonary arterial hypertension via machine learning. , 2020, , .		1
66	Lung perfusion in pulmonary hypertension â€“ results from the RESPIRE study. , 2020, , .		0
67	Multi-omic profiling in pulmonary arterial hypertension. , 2020, , .		0
68	Perioperative management of patients with Pulmonary Hypertension undergoing Non-Cardiac Surgery: A Systemic Review and UK Consensus Statement. , 2020, , .		0
69	REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH). , 2020, , .		0
70	Percent-predicted incremental shuttle walking test distance stratifies risk in pulmonary arterial hypertension. , 2020, , .		0
71	Outcomes measures used in studies of exercise rehabilitation in pulmonary hypertension: a systematic review. , 2020, , .		0
72	CIPHER: a prospective, multicentre study for the identification of biomarker signatures for early detection of pulmonary hypertension. , 2020, , .		0

#	Article	IF	Citations
73	Cardiac MRI right atrial area measurement thresholds for risk stratification in patients with PAH. , 2020, , .		0
74	Arrhythmic Burden and Outcomes in Pulmonary Arterial Hypertension. Frontiers in Medicine, 2019, 6, 169.	1.2	10
75	IodiNe Subtraction mapping in the diagnosis of Pulmonary chronIc thRomboEmbolic disease (INSPIRE): Rationale and methodology of a cross-sectional observational diagnostic study. Contemporary Clinical Trials Communications, 2019, 15, 100417.	0.5	3
76	The incremental shuttle walk test predicts mortality in nonâ€group 1 pulmonary hypertension: results from the ASPIRE Registry. Pulmonary Circulation, 2019, 9, 1-9.	0.8	7
77	Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2019, 9, 1-32.	0.8	96
78	The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulmonary Medicine, 2019, 19, 67.	0.8	45
79	A Systematic Review of Right Ventricular Diastolic Assessment by 4D Flow CMR. BioMed Research International, 2019, 2019, 1-8.	0.9	17
80	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. European Respiratory Journal, 2019, 53, 1801429.	3.1	31
81	Exploring a physiotherapy wellâ€being review to deliver communityâ€based rehabilitation in patients with pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	5
82	A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nature Communications, 2019, 10, 5183.	5.8	22
83	Screening strategies for pulmonary arterial hypertension. European Heart Journal Supplements, 2019, 21, K9-K20.	0.0	44
84	Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	35
85	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	5.2	122
86	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	3.1	110
87	Decision-making in pulmonary endarterectomy surgery. European Respiratory Journal, 2019, 53, 1801973.	3.1	3
88	Diagnosis of Pulmonary Hypertension with Cardiac MRI: Derivation and Validation of Regression Models. Radiology, 2019, 290, 61-68.	3.6	43
89	A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study. , 2019, , .		1
90	Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD). , 2019, , .		1

#	Article	IF	Citations
91	Repeatability and Sensitivity to change of right ventricular analysis methods using cardiac magnetic resonance imaging in PAH: results from the RESPIRE Study. , 2019, , .		2
92	Diagnostic and prognostic value of a diagnostic CT regression model in suspected pulmonary hypertension. , 2019, , .		1
93	Diagnostic accuracy of right ventricular trabecular mass measurements as measured on cardiac MRI in suspected pulmonary hypertension. , 2019, , .		0
94	Late Breaking Abstract - Supplementation of iron in pulmonary hypertension (SIPHON): results from a randomised controlled crossover trial. , 2019, , .		0
95	Thoracic CT features of patients with BMPR2 mutation: preliminary analysis from the UK National Cohort Study of Idiopathic and Heritable PAH. , 2019, , .		0
96	CT pulmonary angiography-derived right atrial area can risk stratify patients with PAH and PH. , 2019, , .		1
97	Reversible pulmonary artery perfusion abnormalities in the postpartum period as a precursor to the development of pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-6.	0.8	1
98	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	5.8	279
99	Current and emerging imaging techniques in the diagnosis and assessment of pulmonary hypertension. Expert Review of Respiratory Medicine, 2018, 12, 145-160.	1.0	7
100	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulmonary Medicine, 2018, 18, 41.	0.8	46
101	Symptom severity and its effect on health-related quality of life over time in patients with pulmonary hypertension: a multisite longitudinal cohort study. BMJ Open Respiratory Research, 2018, 5, e000263.	1.2	28
102	CT derived left atrial size identifies left heart disease in suspected pulmonary hypertension: Derivation and validation of predictive thresholds. International Journal of Cardiology, 2018, 260, 172-177.	0.8	17
103	Reply to Hou et al.: Can Magnetic Resonance Imaging Effectively Evaluate the Prognosis of Patients with Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 676-677.	2.5	0
104	Novel imaging techniques in pulmonary hypertension. Current Opinion in Cardiology, 2018, 33, 587-593.	0.8	5
105	Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 78.	1.6	34
106	High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project. Pulmonary Circulation, 2018, 8, 1-9.	0.8	21
107	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics, 2018, 103, 144-153.	2.6	36
108	Identifying At-Risk Patients with Combined Pre- and Postcapillary Pulmonary Hypertension Using Interventricular Septal Angle at Cardiac MRI. Radiology, 2018, 289, 61-68.	3.6	27

#	Article	IF	Citations
109	Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases â€“ a guide for the generalist. Clinical Medicine, 2018, 18, 329-334.	0.8	34
110	Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility. Frontiers in Cardiovascular Medicine, 2018, 5, 53.	1.1	29
111	Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I. Frontiers in Medicine, 2018, 5, 172.	1.2	4
112	Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease. Frontiers in Medicine, 2018, 5, 174.	1.2	20
113	The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2018, 52, 1800589.	3.1	87
114	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18.	2.6	46
115	Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Chest, 2017, 152, 92-102.	0.4	53
116	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. Journal of Heart and Lung Transplantation, 2017, 36, 770-779.	0.3	73
117	Lung perfusion: MRI vs. SPECT for screening in suspected chronic thromboembolic pulmonary hypertension. Journal of Magnetic Resonance Imaging, 2017, 46, 1693-1697.	1.9	71
118	Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 871-879.	0.3	16
119	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	5.2	99
120	Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 228-239.	2.5	122
121	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, 2017, 9, .	5.8	206
122	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
123	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax, 2017, 72, 1035-1045.	2.7	30
124	British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations. Thorax, 2017, 72, 1154-1163.	2.7	94
125	Pulmonary arteriovenous malformations emerge from the shadows. Thorax, 2017, 72, 1071-1073.	2.7	7
126	A socialâ€technological epistemology of clinical decisionâ€making as mediated by imaging. Journal of Evaluation in Clinical Practice, 2017, 23, 949-958.	0.9	19

#	Article	IF	Citations
127	Longâ€term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue diseaseâ€associated pulmonary arterial hypertension. Respirology, 2017, 22, 372-377.	1.3	12
128	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation, 2017, 135, 460-475.	1.6	154
129	Combining creative writing and narrative analysis to deliver new insights into the impact of pulmonary hypertension. BMJ Open Respiratory Research, 2017, 4, e000184.	1.2	4
130	Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1514-1516.	3.1	35
131	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy. Circulation, 2016, 133, 1761-1771.	1.6	307
132	Pulmonary Hypertension in Patients with Heart Failure and Preserved Ejection Fraction: Differential Diagnosis and Management. Pulmonary Circulation, 2016, 6, 3-14.	0.8	20
133	Diagnosis of Pulmonary Hypertension from Magnetic Resonance Imagingâ€“Based Computational Models and Decision Tree Analysis. Pulmonary Circulation, 2016, 6, 181-190.	0.8	32
134	Pulmonary arterial hypertension associated with congenital heart disease: Comparison of clinical and anatomicâ€“pathophysiologic classification. Journal of Heart and Lung Transplantation, 2016, 35, 610-618.	0.3	21
135	Breathlessness in an ex-miner: an unusual consideration. Thorax, 2016, 71, 481-482.	2.7	1
136	Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute. Pulmonary Circulation, 2015, 5, 435-465.	0.8	230
137	Longitudinal and Transverse Right Ventricular Function in Pulmonary Hypertension: Cardiovascular Magnetic Resonance Imaging Study from the ASPIRE Registry. Pulmonary Circulation, 2015, 5, 557-564.	0.8	15
138	Elevated Plasma CXCL12Î± Is Associated with a Poorer Prognosis in Pulmonary Arterial Hypertension. PLoS ONE, 2015, 10, e0123709.	1.1	27
139	Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 2015, 8, e002569.	1.4	66
140	Triage for suspected acute Pulmonary Embolism: Think before opening Pandora's Box. European Journal of Radiology, 2015, 84, 1202-1211.	1.2	16
141	Right ventricular mass has better reproducibility in systole than diastole in patients with suspected pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P174.	1.6	0
142	Interventricular septal angle can be used to predict which patients have combined postcapillary or precapillary pulmonary hypertension in left heart disease. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P338.	1.6	1
143	Cardiac MRI characteristics in patients with borderline pulmonary hypertension: results from the ASPIRE registry. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P350.	1.6	0
144	Management of acute pulmonary embolism. British Journal of Hospital Medicine (London, England:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.2	2

#	Article	IF	Citations
145	Experimental validation of the hyperpolarized ¹²⁹Xe chemical shift saturation recovery technique in healthy volunteers and subjects with interstitial lung disease. Magnetic Resonance in Medicine, 2015, 74, 196-207.	1.9	76
146	Right Ventricular Sex Differences in Patients with Idiopathic Pulmonary Arterial Hypertension Characterised by Magnetic Resonance Imaging: Pair-Matched Case Controlled Study. PLoS ONE, 2015, 10, e0127415.	1.1	33
147	Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Therapeutic Advances in Respiratory Disease, 2014, 8, 71-77.	1.0	13
148	Dynamic Contrastâ€"Enhanced Magnetic Resonance Imaging in Patients with Pulmonary Arterial Hypertension. Pulmonary Circulation, 2014, 4, 61-70.	0.8	54
149	emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. European Respiratory Journal, 2014, 43, 1106-1113.	3.1	131
150	Magnetic Resonance Imaging of Ventilation and Perfusion Changes in Response to Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 190, e18-e19.	2.5	18
151	LGE Patterns in PulmonaryÂHypertension Do Not ImpactÂOverall Mortality. JACC: Cardiovascular Imaging, 2014, 7, 1209-1217.	2.3	82
152	Prognostic Value of Cardiovascular Magnetic Resonance Imaging Measurements Corrected for Age and Sex in Idiopathic Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging, 2014, 7, 100-106.	1.3	79
153	Quantitative Magnetic Resonance Imaging of Pulmonary Hypertension. Journal of Thoracic Imaging, 2014, 29, 68-79.	0.8	68
154	Management dilemmas in acute pulmonary embolism. Thorax, 2014, 69, 174-180.	2.7	60
155	Pregnancy and pulmonary hypertension: a practical approach to management. Obstetric Medicine, 2013, 6, 144-154.	0.5	36
156	Noninvasive Estimation of PA Pressure, Flow, andÂResistance With CMR Imaging. JACC: Cardiovascular Imaging, 2013, 6, 1036-1047.	2.3	129
157	Improving safety in autologous HSCT for systemic sclerosis. Lancet, The, 2013, 381, 1081-1083.	6.3	4
158	Pulmonary hypertension: diagnosis and management. BMJ, The, 2013, 346, f2028-f2028.	3.0	119
159	Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 294-302.	2.5	153
160	3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax, 2013, 68, 677-678.	2.7	130
161	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The) Tj ETQq1 1 0.784314 rgBT /Overlock		
162	Primary Pulmonary Artery Sarcoma and Coexisting Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, e7-e8.	2.5	7

#	Article	IF	Citations
163	Supplementation of Iron in Pulmonary Hypertension: Rationale and Design of a Phase II Clinical Trial in Idiopathic Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 100-107.	0.8	32
164	Pulmonary hypertension in COPD: results from the ASPIRE registry. European Respiratory Journal, 2013, 41, 1292-1301.	3.1	173
165	Comparison of the Diagnostic Utility of Cardiac Magnetic Resonance Imaging, Computed Tomography, and Echocardiography in Assessment of Suspected Pulmonary Arterial Hypertension in Patients with Connective Tissue Disease. Journal of Rheumatology, 2012, 39, 1265-1274.	1.0	75
166	Serum Osteoprotegerin is Increased and Predicts Survival in Idiopathic Pulmonary Arterial Hypertension. Pulmonary Circulation, 2012, 2, 21-27.	0.8	24
167	Lung Morphology Assessment with Balanced Steady-State Free Precession MR Imaging Compared with CT. Radiology, 2012, 263, 569-577.	3.6	51
168	Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal. European Respiratory Review, 2012, 21, 259-262.	3.0	2
169	Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 790-796.	2.5	483
170	Inhibition of tumor necrosis factorâ€“related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. Journal of Experimental Medicine, 2012, 209, 1919-1935.	4.2	83
171	Pulmonary Artery Relative Area Change Detects Mild Elevations in Pulmonary Vascular Resistance and Predicts Adverse Outcome in Pulmonary Hypertension. Investigative Radiology, 2012, 47, 571-577.	3.5	89
172	Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 31.	1.6	114
173	Black blood MRI has diagnostic and prognostic value in the assessment of patients with pulmonary hypertension. European Radiology, 2012, 22, 695-702.	2.3	37
174	Paigen Dietâ€“Fed Apolipoprotein E Knockout Mice Develop Severe Pulmonary Hypertension in an Interleukin-1â€“Dependent Manner. American Journal of Pathology, 2011, 179, 1693-1705.	1.9	58
175	Survival in Pulmonary Hypertension Registries. Chest, 2011, 139, 1547-1548.	0.4	1
176	Connective Tissue Diseaseâ€“associated Pulmonary Arterial Hypertension in the Modern Treatment Era. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 151-157.	2.5	576
177	Improved Outcomes in Medically and Surgically Treated Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1122-1127.	2.5	379
178	Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism. Respiratory Medicine, 2005, 99, 1286-1291.	1.3	31
179	Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329.	13.9	1,626
180	Management of Suspected Chronic Thromboembolic Pulmonary Hypertension. , 0, , 405-420.		1

#	Article	IF	Citations
181	Unenhanced computed tomography as a diagnostic tool in suspected pulmonary hypertension: a retrospective cross-sectional pilot study. Wellcome Open Research, 0, 6, 249.	0.9	2